{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-141371","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.416457+00:00","generated_at":"2026-06-15T04:27:00.206055+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cabaletta Bio Q1 2023: R&D spend $12.4M; CABA-201 IND cleared, Fast Track granted","bullets":["R&D expenses $12.4M (Q1 2023) vs $9.2M (Q1 2022); G&A $4.5M vs $3.8M.","Cash and equivalents $93.8M as of March 31, 2023; runway into Q1 2025.","FDA cleared IND for CABA-201 Phase 1/2 trial in lupus nephritis and SLE; Fast Track Designation granted.","Trial to enroll 6 LN and 6 SLE patients at 1.0x10^6 cells/kg; three-month efficacy data expected H1 2024.","Preclinical and updated DSG3-CAART data to be presented at ASGCT 26th Annual Meeting May 16-20."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-141371","json":"https://secwatch.observer/filing/0001193125-23-141371.json","markdown":"https://secwatch.observer/filing/0001193125-23-141371.md","text":"https://secwatch.observer/filing/0001193125-23-141371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523141371/0001193125-23-141371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523141371/d669630d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:27:00.206055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"080defe974723f5df3ec71d976f266921ecdd8fe","claim":"Cabaletta Bio, Inc. reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523141371/0001193125-23-141371-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}